Prognosis
NIH to Study Allergic Reactions Linked to Covid-19 Shot
- Goal is to predict, manage incidents, Warp Speed adviser says
- U.K. variant not more dangerous, unclear if more transmissible
A vial of the Pfizer-BioNTech COVID-19 vaccine.
Photographer: Mark Lennihan/Pool APThis article is for subscribers only.
The National Institutes of Health plans to begin a clinical trial that aims to help doctors “predict and manage” allergic reactions related to Pfizer Inc.’s Covid-19 vaccine.
Moncef Slaoui, chief scientific adviser to Operation Warp Speed, said during a Monday news briefing that the aim of the trial, which will also study the Moderna Inc. shot just authorized for emergency use, will be to pinpoint why the incidents, known as anaphylaxis, are occurring.